Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting [Yahoo! Finance]
Immunome, Inc. (IMNM)
Company Research
Source: Yahoo! Finance
best-in-class targeted cancer therapies, today announced that it will present preclinical data for IM-3050, the company's lead lutetium-177 radioligand therapy (RLT) targeting fibroblast activation protein (FAP). Jack Higgins, PhD, Chief Scientific Officer at Immunome, will present the data in a poster at the American Association for Cancer Research (AACR) Annual Meeting 2024, which is taking place April 5-10 in San Diego, California. "FAP is an attractive target for cancer therapy, but trials with first-generation FAP-RLTs have produced modest clinical responses, indicating the need for novel agents with improved therapeutic properties," commented Dr. Higgins. "We believe IM-3050 has best-in-class potential and look forward to sharing preclinical data for the program at AACR." Immunome expects to submit an Investigational New Drug application to the U.S. Food & Drug Administration for IM-3050 in the first quarter of 2025. Poster Presentation Details: Title: A novel lutetium-1
Show less
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for [Yahoo! Finance]Yahoo! Finance
- Immunome Appoints Sandra M. Swain to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Immunome Appoints Sandra M. Swain to Board of DirectorsBusiness Wire
- Immunome, Inc. (NASDAQ: IMNM) is now covered by analysts at Guggenheim. They set a "buy" rating and a $35.00 price target on the stock.MarketBeat
- Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling [Seeking Alpha]Seeking Alpha
IMNM
Sec Filings
- 4/29/24 - Form 4
- 4/29/24 - Form 3
- 4/26/24 - Form ARS
- IMNM's page on the SEC website